使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and thank you for standing by. Welcome to the BioCryst third quarter 2026 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.
各位好,感謝您耐心等候。歡迎參加 BioCryst 2026 年第三季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。
I would now like to hand the conference over to your first speaker today, Nick Wilder with BioCryst. Nick, go ahead.
現在我想把會議交給今天的第一位講者,BioCryst 的 Nick Wilder。Nick,請開始。
Nick Wilder - Manager, Investor Relations
Nick Wilder - Manager, Investor Relations
Good morning, and welcome to BioCryst's third quarter 2026 corporate update and financial results conference call. Participating with me today are President and CEO, Charlie Gayer; Chief Financial Officer, Babar Ghias; and Chief R&D Officer, Dr. Sandeep Menon. A press release and slide presentation about today's news are available on our Investor Relations website.
各位早安,歡迎參加 BioCryst 2026 年第三季公司營運更新與財務結果電話會議。今天與我一同出席的有總裁兼執行長 Charlie Gayer;財務長 Babar Ghias;以及研發長 Sandeep Menon 博士。關於今日消息的新聞稿與簡報投影片已發布於我們投資人關係網站。
Today's call contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and/or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide 2 of the presentation.
今天的電話會議包含前瞻性陳述,包括有關未來結果、未經審計及前瞻性的財務資訊,以及公司未來表現和/或成就的陳述。這些陳述受到已知與未知風險及不確定性的影響,可能導致我們的實際結果、表現或成就與本簡報中明示或暗示的任何未來結果或表現存在重大差異。如需更多資訊(包括對這些風險的詳細討論),請參閱簡報第 2 頁。
In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our investor relations website.
此外,今天的電話會議包含非 GAAP 財務衡量指標。如需將這些非 GAAP 財務衡量指標與最直接可比的 GAAP 財務衡量指標進行調節(reconciliation),請參閱我們投資人關係網站上的財報新聞稿。
I'd now like to turn the call over to Charlie.
現在我想把電話會議交給 Charlie。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, Nick. The third quarter was significant for BioCryst as we continued to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for ORLADEYO continued at the same high level that we have seen all year. We again added new prescribers at a rate above the average of the past several years, and the total base of treated patients grew at a healthy rate in the quarter.
謝謝你,Nick。第三季對 BioCryst 而言意義重大,因為我們在策略演進的同時,持續展現強勁的執行力。在 HAE 方面,ORLADEYO 的新病患處方量持續維持在我們今年以來所見的同樣高水準。我們新增開立處方的醫師數量再次以高於過去數年平均的速度成長,而本季接受治療的病患總基數也以健康的速度增加。
We were thrilled to launch ORLADEYO pellets to kids in August, and early signs of performance continue to be promising. Children of all ages across the 2 to 11 range have started on ORLADEYO pellets, and the mix of kids switching from other prophy and acute only, as well as those who were treatment naive, has been balanced. This suggests the pediatric market may grow beyond the 500 patients that we have previously described.
我們很高興在 8 月將 ORLADEYO 顆粒劑(pellets)推向兒童族群,且早期的表現跡象仍然令人鼓舞。2 至 11 歲各年齡層的兒童都已開始使用 ORLADEYO 顆粒劑;在病患組成方面,從其他預防用藥(prophy)與僅急性用藥(acute only)轉換而來者,以及先前未曾接受治療者(treatment naive),比例相當均衡。這顯示兒科市場可能會超出我們先前所描述的 500 名病患規模。
We are also looking forward to launching the recently approved 150 mg ORLADEYO pellets at the upcoming American College of Allergy, Asthma, and Immunology meeting this month. This new formulation for ages 12 and up provides an option for kids who started on pellets, for adolescents and adults who have difficulty swallowing a capsule, or for anyone who simply prefers the pellet formulation. We are looking forward to generating real-world evidence to track the progress and patterns of use for all patients treated with ORLADEYO pellets.
我們也期待在本月即將舉行的美國過敏、氣喘與免疫學學會(American College of Allergy, Asthma, and Immunology)年會上,推出近期獲核准的 150 mg ORLADEYO 顆粒劑。此一適用於 12 歲以上的新劑型,為已開始使用顆粒劑的孩童、吞嚥膠囊有困難的青少年與成人,或任何單純偏好顆粒劑型的人提供另一種選擇。我們期待產生真實世界證據(real-world evidence),以追蹤所有接受 ORLADEYO 顆粒劑治療病患的進展與使用模式。
During the third quarter, we also implemented the transition to CareMed as our sole source pharmacy partner for shipments to patients. We switched to CareMed because the volume of patients on ORLADEYO has grown to the point where operational excellence at the pharmacy level can have a significant impact on the growth in treated patients and the shipment in paid product.
在第三季期間,我們也完成轉換,將 CareMed 作為我們唯一的藥局合作夥伴,負責向病患出貨。我們改用 CareMed,是因為使用 ORLADEYO 的病患量已成長到一個程度,使得藥局端的營運卓越能對接受治療病患數的成長,以及付費產品出貨量帶來顯著影響。
We are working closely with CareMed to integrate best practices within our Empower Patient Services program and are encouraged by the early signs we are seeing in the partnership. We believe CareMed can scale with us as our portfolio of HAE prophy offerings continues to grow.
我們正與 CareMed 緊密合作,將最佳實務整合至我們的 Empower Patient Services 計畫中,且對於合作關係所呈現的早期正向跡象感到鼓舞。我們相信,隨著我們的 HAE 預防(prophy)產品組合持續擴大,CareMed 能與我們一同擴充規模。
Turning to our pipeline, as we have previously announced, the pivotal trial for navenibart fully enrolled in June, and we remain on track to announce top-line data through 12 months of therapy in the third quarter of next year. Our team is working diligently on the BLA file, as well as launch planning for when we add this potentially transformative product to our HAE portfolio.
談到我們的研發管線,如同先前所宣布,navenibart 的關鍵性試驗已於 6 月完成全數收案(fully enrolled),我們仍按計畫在明年第三季公布治療 12 個月的主要結果(top-line data)。我們的團隊正積極推進 BLA 申請文件,同時也為將這項可能具變革性的產品納入我們的 HAE 產品組合後的上市規劃做準備。
Continuing on the theme of strong execution, we have enrolled part four of our trial of BCX17725 for Netherton syndrome patients and are on track to have early clinical data by the end of this year. There are no treatments approved for this devastating skin condition that we believe includes at least 3,000 patients in the U.S. alone. Once the data reads out, we will review the data in totality, which includes key efficacy endpoints like IASI, the Ichthyosis Area and Severity Index score, as well as safety and tolerability to inform potential next steps in the program.
延續強勁執行的主題,我們已完成 BCX17725 針對 Netherton 症候群病患試驗的第四部分收案,並預計在今年底前取得早期臨床數據。對於這種毀滅性的皮膚疾病,目前尚無核准治療方式;我們認為僅在美國就至少有 3,000 名病患。待數據讀出後,我們將就整體數據進行審視,其中包括關鍵療效終點(例如 IASI,即魚鱗病面積與嚴重度指數分數),以及安全性與耐受性,以作為該計畫後續可能步驟的依據。
Finally, we are excited about our strategic shift toward building our pipeline through external innovation. We recently announced a Scientific Advisory Board of leading biotech industry experts who will partner with us to deliver on our strategy. These esteemed advisors, with a successful track record, did not join us just for the honor of being on the board. They joined us because they believe that BioCryst's profitability, discipline, and strong execution position the company for success in our rare disease strategy.
最後,我們對於透過外部創新來打造研發管線的策略轉向感到振奮。我們近期宣布成立由生技產業領先專家組成的科學顧問委員會(Scientific Advisory Board),將與我們合作推動策略落地。這些備受尊敬且具成功實績的顧問加入我們,並非只是為了擔任委員的榮譽。他們加入是因為相信 BioCryst 的獲利能力、紀律性與強勁執行力,使公司在罕見疾病策略上具備成功的有利定位。
With that, I'll turn it over to Babar to describe our increasingly strong financial position.
接下來,我把時間交給 Babar,說明我們日益強健的財務狀況。
Babar Ghias - Chief Financial Officer
Babar Ghias - Chief Financial Officer
Thanks, Charlie. We are pleased to share the results of a very strong third quarter, which included not only the important accomplishments just described, but also continued financial excellence. The intentional, proactive steps we have taken throughout the year to position BioCryst for durable growth and increasing profitability continue to be reflected in our financial performance.
謝謝你,Charlie。我們很高興分享第三季非常強勁的成果,除了剛才所述的重要里程碑外,也包括持續的財務卓越表現。我們在今年以來所採取的有意識且主動的措施,用以讓 BioCryst 具備可持續的成長與更高的獲利能力,持續反映在我們的財務表現上。
In my remarks today, I will refer to certain non-GAAP financial measures, which adjust for revenues and expenses associated with our former European ORLADEYO business, stock-based comp, Birmingham site closure, and organizational restructuring costs, and expenses associated with the Astria acquisition. Additional information regarding these adjustments is included in today's press release. We believe these non-GAAP measures provide investors with a useful view of the underlying performance of the ongoing business. Now, turning first to revenue.
在我今天的發言中,我將提及若干非 GAAP 財務衡量指標;這些指標會調整與我們先前歐洲 ORLADEYO 業務相關的收入與費用、以股票為基礎的薪酬(stock-based comp)、伯明罕據點關閉、組織重整成本,以及與 Astria 收購案相關的費用。關於這些調整的更多資訊已包含在今天的新聞稿中。我們相信,這些非 GAAP 指標能為投資人提供一個有用的視角,以了解持續經營業務的基本面表現。現在先從營收談起。
ORLADEYO net revenue was $174.8 million for the quarter, with more than 95% coming from the U.S. business. On a comparable basis, excluding European revenue, ORLADEYO revenue increased 20% year-over-year. ORLADEYO revenues benefited this quarter from the CareMed transition.
本季 ORLADEYO 淨營收為 1.748 億美元,其中超過 95% 來自美國業務。以可比基礎計算(排除歐洲營收),ORLADEYO 營收年增 20%。本季 ORLADEYO 營收亦受惠於轉換至 CareMed。
One of the benefits of switching to a larger specialty pharmacy is that they maintain a level of inventory at multiple sites and broader set of working operation hours that facilitate timely fulfillment to efficiently respond to patient demand. The inventory they hold typically ranges from one to three weeks of product. As part of the transition to this model, CareMed built an inventory level towards the lower end of this range during the third quarter, resulting in a revenue contribution in the upper teens of millions of dollars in the quarter.
改用規模更大的專科藥局(specialty pharmacy)的其中一項好處,是其在多個據點維持一定水準的庫存,並具備更廣泛的營運工時,有助於及時履約(fulfillment),以有效回應病患需求。其持有的庫存通常約為一至三週的產品量。作為轉換至此模式的一部分,CareMed 在第三季將庫存水準建立至該區間的較低端,因而在本季帶來約數千萬美元高十位數(upper teens)的營收貢獻。
Since we expect their inventory level to remain in this lower end, revenue should more closely reflect underlying patient demand going forward. While a transition of this nature naturally creates some temporary operational complexity as systems and processes are implemented, we are very pleased with the progress to date. Although it is still early, we are already seeing an improvement in days to first shipment for new patients, an important measure of the patient experience.
由於我們預期其庫存水位將維持在較低區間,未來營收應會更貼近潛在的病患需求。雖然此類轉換在系統與流程導入期間自然會帶來一些暫時性的營運複雜度,但我們對目前為止的進展感到非常滿意。儘管仍屬早期,我們已經看到新病患首次出貨天數有所改善,這是衡量病患體驗的重要指標。
Despite the transition, even when removing the impact of the inventory build, ORLADEYO revenue, excluding Europe, grew year-over-year. This is evidence of the continued favorable patient dynamics across the approved population. Throughout this process, our priority has remained the same, maintaining a high-quality patient experience and uninterrupted access to ORLADEYO.
儘管處於轉換期間,即使剔除庫存建立的影響,ORLADEYO(不含歐洲)營收仍較去年同期成長。這證明在已核准適應症族群中,病患動態仍持續有利。在整個過程中,我們的優先事項始終不變:維持高品質的病患體驗,並確保對 ORLADEYO 的取得不中斷。
Before turning to operating expenses, let me briefly provide some context around the GAAP to non-GAAP adjustments this quarter. These adjustments primarily relate to the closure of our Birmingham facility and associated organizational restructuring activities that remain on track to be substantially completed by year-end.
在談到營運費用之前,我先簡要說明本季 GAAP 與非 GAAP 調整項目的背景。這些調整主要與我們關閉伯明罕(Birmingham)廠區,以及相關的組織重整活動有關;目前進度符合預期,預計在年底前大致完成。
Of the approximately $19 million in restructuring-related expenses in the quarter, only $10 million are real cash costs. Non-cash charges primarily reflected accounting adjustments to assets that no longer will have economic use following the closure.
本季約 1,900 萬美元的重整相關費用中,只有 1,000 萬美元屬於實際現金成本。非現金費用主要反映對資產的會計調整,因為在關廠後這些資產將不再具有經濟用途。
The most important takeaway today is the structural benefit to our cost base. The actions we have taken are expected to generate approximately $30 million to $35 million of annualized savings once fully realized, with the potential for additional savings as certain programs are wound down.
今天最重要的重點是我們成本基礎的結構性改善。我們已採取的行動,預期在完全落實後可帶來約 3,000 萬至 3,500 萬美元的年化節省;隨著部分計畫逐步結束,仍有額外節省的可能。
As we look toward 2027, the business as it exists today is positioned for continued revenue growth alongside a lower operating cost base than in 2026. We will provide formal 2027 guidance at the appropriate time, but the combination should support continued expansion in profitability. Turning now over to operating expenses.
展望 2027 年,以目前的業務狀態來看,我們有望在持續營收成長的同時,擁有較 2026 年更低的營運成本基礎。我們將在適當時點提供正式的 2027 年財測指引,但這樣的組合應可支持獲利能力持續擴張。接下來談營運費用。
Non-GAAP operating expenses were slightly lower year-over-year, consistent with the financial discipline we have been emphasizing. We are actively investing in the Phase III development program for navenibart, which is naturally an important driver of R&D spending.
非 GAAP 營運費用較去年同期略為下降,符合我們一直強調的財務紀律。我們正積極投資 navenibart 的第三期(Phase III)開發計畫,這自然是研發支出的重要驅動因素。
At the same time, we are taking a disciplined, data-driven approach to capital allocation across the rest of the pipeline. BCX17725 is a good example. Our approach has been to generate early clinical data in patients first, and let that data prospectively inform the appropriate level of future investment. We remain on track to share those data before year-end.
同時,對於其餘研發管線的資本配置,我們採取嚴謹、以數據為導向的方法。BCX17725 就是一個很好的例子。我們的做法是先在病患中取得早期臨床數據,再讓這些數據以前瞻方式決定未來適當的投資水準。我們仍按計畫在年底前分享這些數據。
Sales and marketing expenses were modestly higher year-over-year, driven primarily by the transition-related fees associated with the specialty pharmacy arrangement. G&A expense has remained essentially flat. This operating leverage from the trends is increasingly visible in our results. Non-GAAP operating profit for the quarter was $86 million, an increase of 70% year-over-year, while non-GAAP net income of $71 million more than doubled from the prior year period.
銷售與行銷費用較去年同期小幅增加,主要由與專科藥局安排相關的轉換費用所帶動。一般與行政(G&A)費用基本持平。這些趨勢帶來的營運槓桿效益在我們的業績中愈來愈明顯。本季非 GAAP 營運利益為 8,600 萬美元,較去年同期成長 70%;非 GAAP 淨利為 7,100 萬美元,較去年同期增加逾一倍。
As profitability continues to grow, we also expect to benefit from our substantial net operating loss carryforwards, which should help limit cash taxes over the medium term, subject to applicable tax rules and limitations. That creates the potential for strong growth not only in earnings, but also in cash generation.
隨著獲利持續成長,我們也預期可受惠於可觀的淨營運虧損結轉(NOL)餘額,在中期內有助於限制現金稅負,但仍須遵循適用的稅法規則與限制。這使我們不僅在盈餘上,也在現金創造能力上具備強勁成長的潛力。
Our liquidity position remains strong, with cash and equivalents of $376 million. As we have discussed, we have made a deliberate pivot toward external innovation, but we are going to remain disciplined in how we build the pipeline.
我們的流動性部位仍然強勁,現金及約當現金為 3.76 億美元。如同我們先前討論的,我們已刻意轉向外部創新,但在建立研發管線的方式上仍會保持紀律。
For us, the priority is not adding programs simply to increase the size of the pipeline. It is identifying opportunities where we believe BioCryst can create meaningful value for patients and shareholders. At the same time, we will always continue to evaluate opportunities to strengthen the balance sheet and return capital, while maintaining the financial flexibility to invest in compelling innovation. Turning finally to our 2026 financial guidance.
對我們而言,優先事項不是為了擴大管線規模而單純增加專案。而是辨識我們相信 BioCryst 能為病患與股東創造實質價值的機會。同時,在維持投資具吸引力創新的財務彈性之下,我們也會持續評估強化資產負債表與回饋資本的機會。最後談我們 2026 年的財務指引。
When we established our ORLADEYO revenue guidance, we did not assume a benefit from the initial specialty pharmacy inventory build. Given that we still remain relatively early in the CareMed transition implementation, we are not changing ORLADEYO revenue guidance at this time. We are encouraged by the progress we are seeing, but we also recognize that we are transitioning six years of launch experience, systems, and operating knowledge from one partner to another on an accelerated timeline.
在我們制定 ORLADEYO 營收指引時,並未假設初期專科藥局庫存建立會帶來助益。鑑於我們在 CareMed 轉換導入上仍處於相對早期階段,目前不調整 ORLADEYO 的營收指引。我們對目前看到的進展感到鼓舞,但也理解我們正以加速時程,將六年的上市經驗、系統與營運知識從一個合作夥伴移轉到另一個合作夥伴。
Importantly, we view this as a finite transition and not a long-term operating dynamic. Underlying patient demands and trends remain strong, and we are excited about the opportunity to expand the pediatric launch while also offering the newly approved oral pellet formulation for patients with HAE 12 years and older, providing a continuum of oral treatment options.
重要的是,我們將此視為有限期的轉換,而非長期的營運常態。潛在病患需求與趨勢仍然強勁;我們也對擴大兒科上市機會感到振奮,同時為 12 歲及以上 HAE 病患提供新近核准的口服顆粒劑型,形成一套連續性的口服治療選項。
On the other hand, we are increasing our total revenue guidance to $715 million to $730 million, reflecting higher realized licensing revenue and international RAPIVAB orders from our partner. To emphasize, RAPIVAB is not a strategic core asset for us and is mostly a pass-through business with low margins.
另一方面,我們將總營收指引上調至 7.15 億至 7.30 億美元,反映已實現的授權收入較高,以及合作夥伴帶來的國際 RAPIVAB 訂單增加。需要強調的是,RAPIVAB 並非我們的策略核心資產,且多屬於低毛利的轉手型業務。
On expenses, we are again tightening our full-year operating expense guidance now to $415 million to $425 million for 2026. When we realize the full-year benefit of the actions we have taken in 2026, we expect operating expenses in 2027 to decline further while the underlying business continues to grow.
在費用方面,我們再次收緊 2026 年全年營運費用指引至 4.15 億至 4.25 億美元。當我們在 2026 年採取的行動於 2027 年完整反映全年效益時,預期營運費用將進一步下降,同時核心業務仍將持續成長。
To close, this was a very strong third quarter and strong first nine months of 2026. We have one quarter remaining, and our focus is on finishing the year well and entering 2027 from a position of considerable strength. With growing revenue and increasingly efficient cost structure, expanding profitability, strong liquidity, and important pipeline catalysts ahead, we believe we have the opportunity to make 2027 a transformational year for BioCryst. The entire organization is focused on executing against the opportunity, and I am very grateful to our colleagues across BioCryst for everything they have accomplished this year.
總結來說,這是一個非常強勁的第三季,也是 2026 年前九個月的強勁表現。我們還剩下一季,我們的重點是把今年收好,並以相當強勢的姿態進入 2027 年。在營收成長、成本結構日益高效、獲利能力擴張、流動性強勁,以及前方重要研發管線催化劑的帶動下,我們相信 2027 年有機會成為 BioCryst 的轉型之年。整個組織都專注於把握這個機會並落實執行;我也非常感謝 BioCryst 各地同仁今年所完成的一切。
With that, operator, we are now ready to take questions.
接下來,主持人,我們已準備好開始回答問題。
Operator
Operator
(Operator Instructions) Gavin Clark-Gartner, Evercore ISI.
(主持人指示) Gavin Clark-Gartner,Evercore ISI。
Gavin Clark-Gartner - Analyst
Gavin Clark-Gartner - Analyst
Hey, guys. Great to see the progress, and thanks for taking the question. I guess, first, just to clarify on the inventory. So there was upper teens contribution from the CareMed inventory build. How should we expect that to trend next quarter? Will there be a reversal of a similar amount? Is there some level of inventory build still to happen here? What should we think about next quarter?
嗨,各位。很高興看到進展,也謝謝讓我提問。我想先釐清一下庫存的部分。所以 CareMed 的庫存建立帶來了約十幾個百分點(upper teens)的貢獻。我們應該如何看待下季的走勢?會不會出現類似幅度的回轉?這裡是否還有一定程度的庫存建立尚未完成?對於下季我們應該怎麼思考?
Babar Ghias - Chief Financial Officer
Babar Ghias - Chief Financial Officer
Yeah, thanks for the question, Gavin. So I think your intuition is correct. It's a one-time inventory build that they have for dispensing. And our expectation is that, as I mentioned in the call, that typically they hold 7 to 21 days of inventory. And in this quarter, we were on the lower side of that range, and we expect that to remain in the lower side. So you are not going to expect a one-time benefit or, I guess, a recurring benefit of inventory every quarter from this point onwards.
好的,謝謝你的問題,Gavin。我想你的直覺是對的。這是他們為了配藥而進行的一次性庫存建立。我們的預期是,如同我在電話會議中提到的,他們通常會持有 7 到 21 天的庫存。而在本季,我們處於該區間的較低端,並預期將維持在較低端。因此,從現在開始,你不應該期待每一季都會有一次性的庫存利益,或者說持續性的庫存利益。
There may be, in the nearer term, in another quarter, there may be small fluctuations, but as it gets smoothed out, it should reflect patient demand. So to summarize, it was really a one-time benefit of this order of magnitude, and that should be the expectation.
在較近的短期內,可能在下一季左右,會出現一些小幅波動,但隨著情況逐步平滑化,它應該會反映病患需求。因此總結來說,這確實是一次性的、約在這個量級的利多,而這也應該是大家的預期。
Gavin Clark-Gartner - Analyst
Gavin Clark-Gartner - Analyst
Okay, great. That's helpful. Just quickly, quick follow-up. What was the pediatric prescriptions that you saw this quarter?
好的,很棒。這很有幫助。再快速追問一下。你們這一季看到的小兒處方量是多少?
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
We're not going to get into the specific numbers, Gavin, but it continued to be strong. We had announced at the end, I think it was at the end of July, we had 47. That was well ahead of our expectations for the year. We continue ahead of our expectations.
Gavin,我們不會談具體數字,但它持續表現強勁。我們在期末宣布過,我想是在七月底,我們有47。那遠超出我們對今年的預期。我們仍然領先於我們的預期。
The pediatric revenue we generate is still going to be a very small part of this year's revenue, but it's a good sign for the future. And like I mentioned, we're looking forward to starting to collect real-world evidence in this population, so I think we'll have more to report out in the future as a little more time passes
我們產生的小兒營收仍將只占今年營收的很小一部分,但這對未來是個好兆頭。而且如我提到的,我們期待開始在這個族群收集真實世界證據,所以我想隨著時間再過一點,未來我們會有更多可以對外分享的內容
Gavin Clark-Gartner - Analyst
Gavin Clark-Gartner - Analyst
Perfect. Thanks, guys.
完美。謝謝各位。
Operator
Operator
Laura Chico, Wedbush.
Laura Chico,Wedbush。
Laura Chico - Analyst
Laura Chico - Analyst
Good morning. Thanks very much for taking the question. I guess I wanted to ask one more strategic. Could you expand on your commentary around the 2033 and beyond outlook for the HAE franchise? If I am looking at the slides correctly, it looks like you are describing it as a range from about $1.4 billion to $2.0 billion in 2033.
早安。非常感謝讓我提問。我想我還想再問一個更偏策略面的問題。你們能否進一步說明對HAE產品線在2033年及之後的展望的評論?如果我沒看錯投影片,你們似乎將2033年的範圍描述為約14億美元到20億美元。
I think before you talked about this as a $1.8 billion plus opportunity. So I guess, help us understand some of the dynamics there that go into the lower and upper bounds. What needs to go right? I guess, has anything changed to shift your outlook? Thank you.
我記得你們之前談的是18億美元以上的機會。所以,請幫我們理解一下,哪些動態因素會形成這個下限與上限。哪些事情需要進展順利?我想問的是,有沒有任何變化導致你們調整展望?謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, Laura. The range that we provide is actually based on sell-side analyst views of the portfolio, and we put it out there because directionally, we agree with the two products with the most established oral at that point, the market-leading oral prophy, and then what we think will be really a transformative product with every three- and six-month dosing with Navenibart.
謝謝,Laura。我們提供的區間其實是基於賣方分析師對該產品組合的看法;我們把它放出來是因為在方向上,我們同意到那個時間點會有兩個最成熟的口服產品:市場領先的口服預防用藥,以及我們認為將帶來真正變革、可每三個月與每六個月給藥一次的Navenibart。
It really allows us to hit both big segments of the market, those who prefer oral prophy, those who prefer injectable prophy. And so the things that need to go right for that to happen, obviously, is continued growth of ORLADEYO, which we expect, and all of our forward-looking research metrics tell us that that will continue and then a strong launch that we are preparing for Navenibart.
這確實讓我們能同時覆蓋市場的兩大族群:偏好口服預防的人,以及偏好注射型預防的人。因此,要達成那樣的結果,顯然需要幾件事進展順利:ORLADEYO持續成長(我們預期會如此),而且我們所有前瞻性的研究指標都顯示這將會延續;另外就是我們正在為Navenibart做準備,需要一個強勁的上市推廣。
What we see in our research with doctors and patients is that that three and six-month dosing with high efficacy and with a convenient administration is something that gets their attention and will encourage patients to switch. So the real key is going to be how many of the patients who are on other injectable PROFIs want to take advantage of this longer-term dosing and switch. That will be the key driver of kind of the pace of our revenue growth and kind of the ultimate peak of where we get with Navenibart.
我們在對醫師與病患的研究中看到,三個月與六個月一次的給藥頻率、加上高療效與便利的給藥方式,確實能引起他們的注意,並會鼓勵病患轉換。所以真正的關鍵將在於:目前使用其他注射型預防(PROFI)療法的病患中,有多少人想利用這種更長間隔的給藥而轉換。這將是驅動我們營收成長速度,以及Navenibart最終峰值能到哪裡的關鍵因素。
Laura Chico - Analyst
Laura Chico - Analyst
Thanks, Charlie.
謝謝,Charlie。
Operator
Operator
Steve Seedhouse, Cantor.
Steve Seedhouse,Cantor。
Steve Seedhouse - Analyst
Steve Seedhouse - Analyst
Great. Thanks for taking the question. Sort of related to the long-term revenue projections, but specifically as it pertains to ORLADEYO and just the stickiness of that, have you guys done any updated market research post the deucrictibant prophylaxis Phase III result, and do you have a sense that that was above, below, or in line with expectations of what you've been modeling really for the past several years? Thanks.
很好。謝謝讓我提問。這有點和長期營收預測相關,但更具體地說,關於ORLADEYO以及其黏著度(stickiness),你們在deucrictibant預防適應症第三期結果出來之後,有沒有做任何更新的市場研究?你們是否覺得該結果高於、低於或符合你們過去幾年模型中的預期?謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, Steve. We have not done specific research since the data came out. However, what we did do is our annual large exercise that we do the middle of every year, where we talk to 175 HAE treaters, 100 patients, 50 payers, and run it through a big conjoint exercise and market simulation model. What we put in there for deucrictibant, recall that we always put all of our current and future competition in with their best-case profile. And so the profile that we put in for deucrictibant was actually slightly better than the actual, what they proved out in the Phase III.
謝謝,Steve。數據出來之後,我們沒有做針對性的研究。不過,我們確實做了每年年中都會進行的大型年度研究:我們訪談175位HAE治療醫師、100位病患、50位付款方,並透過大型聯合分析(conjoint)與市場模擬模型來運算。我們在其中納入deucrictibant時,請記得我們一向會把所有現有與未來競品都以其最佳情境的產品特性(best-case profile)放進去。因此,我們對deucrictibant放入的產品特性其實比他們在第三期證實的實際結果略好一些。
So comparable, but slightly better. And it showed that, yes, that product will gain share, as you would expect, but what it's not going to do is take away the base of ORLADEYO patients. We continue to see ORLADEYO growing even in the face of future competition in a couple years from deucrictibant.
所以是相近,但略好。結果顯示,是的,那個產品會如預期取得市占,但它不會侵蝕ORLADEYO病患的基本盤。即使面對未來幾年deucrictibant帶來的競爭,我們仍然看到ORLADEYO持續成長。
Steve Seedhouse - Analyst
Steve Seedhouse - Analyst
Terrific. Thank you.
太好了。謝謝。
Operator
Operator
Stacy Ku, TD Cowen.
Stacy Ku,TD Cowen。
Stacy Ku - Equity Analyst
Stacy Ku - Equity Analyst
Thanks so much for taking our questions. We have a couple of clarifications. So first, maybe can you talk about -- given your inventory commentary, really appreciate all the detailed thoughts there, your level of confidence in the high end of ORLADEYO guidance that you provided for the year? That is just a follow-up on inventory.
非常感謝回答我們的問題。我們有幾點需要釐清。第一,或許你們能談談——考量你們對庫存的評論(非常感謝你們提供那麼多細節),你們對今年所提供的ORLADEYO財測區間上緣的信心程度如何?這是針對庫存的追問。
And then second, on the pediatric launch, would you characterize it more as steady additions, or are you seeing a bit of a bolus type of dynamic for the pediatric prescriptions? As we look to next year and consensus, I know you will not comment, but does that include what you are seeing for the pediatric launch, or would you look at that as upside?
第二,關於小兒上市,你們會把它描述為穩定新增,還是你們看到小兒處方有點像「一次性大量湧入(bolus)」的動態?我們看明年的市場共識(我知道你們不會評論),那是否已包含你們目前看到的小兒上市表現,或你們會把它視為上行空間?
And then third clarification, when we speak to clinicians, they tend to have their patients track very detailed data on their attacks for payer reimbursement and access. So as you are looking at the oral competitive landscape in the next couple of years, do you have a good sense of the percentage of patients that are well-controlled on ORLADEYO, so having really competitive attack rate reductions, as folks try to understand the stickiness of the drug? Thanks so much.
第三點釐清,當我們與臨床醫師交流時,他們往往會讓病患追蹤非常詳細的發作數據,以利付款方的給付與可近性。因此,當你們看未來幾年的口服競爭格局時,你們是否掌握一個不錯的估計:有多少比例的病患在ORLADEYO下控制良好,也就是發作率下降幅度非常具競爭力,讓大家能理解這個藥物的黏著度?非常感謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Great. Thanks, Stacy. Maybe I'll take -- go through the second question with all those pieces, then we'll come back and Babar can talk about the inventory.
很好。謝謝,Stacy。也許我先回答——把第二個問題的各個部分先過一遍,然後我們再回來由Babar談庫存。
So on the pediatrics, number one, what we're seeing is kind of steady, strong additions. So there was, of course, a bolus at first, particularly because of the supply delay that we had. There was a bolus to start. Those patients have been transitioned to therapy. And then we're seeing continued strong demand that is ahead of what our original expectations are. It's still only been a few months, so we'll have to see how long this continues, but the early signs are very promising.
關於小兒方面,第一,我們看到的是相對穩定、且強勁的新增。當然,一開始確實有一波「大量湧入(bolus)」,特別是因為我們之前有供應延遲。一開始有一波湧入。那些病患已經轉入治療。接著我們看到持續強勁的需求,且高於我們原先的預期。目前也才幾個月,所以還要觀察這樣的趨勢能持續多久,但早期跡象非常令人鼓舞。
As we kind of look to the future of ORLADEYO, when we give guidance for 2027, pediatrics will be absolutely a part of all of that. And then when we have additional data that's, as I've mentioned, real-world evidence, when we generate other evidence that we think is interesting and helpful, we may comment on other pieces of how pediatrics breaks out of the whole bit.
當我們某種程度上展望 ORLADEYO 的未來時,在我們提供 2027 年的指引時,小兒科絕對會是其中的一部分。接著,當我們有更多資料——如我提到的真實世界證據——當我們產生其他我們認為有趣且有幫助的證據時,我們可能會就小兒科在整體中如何拆分的其他面向加以評論。
And then as far as patients, the patients who are well-controlled on ORLADEYO, you've heard us talk before about when patients start, 60% of them roughly get to 12 months of therapy. And then those patients are largely the very well-controlled. So those are the ones who are getting down to a median attack rate. We've put out real-world evidence on this, where they're getting down to a median attack rate of about a third of an attack per month.
至於病人方面,對於使用 ORLADEYO 控制良好的病人,你們之前也聽我們談過,病人開始治療後,大約有 60% 能持續治療到 12 個月。而這些病人大多是控制得非常好的。因此,他們的發作率會降到一個中位數水準。我們已發布過相關的真實世界證據,顯示他們的中位數發作率可降至每月約三分之一(0.33 次)發作。
And patients generally are reporting significant reductions in attack rates regardless of where they're coming from, whether they switch from other prophylaxis or were not previously on prophylaxis So we feel like we're holding onto the patients who are doing well. They're getting market-competitive efficacy.
而且病人普遍回報發作率顯著下降,不論他們原本的狀況如何——不論是從其他預防性治療轉換過來,或先前未接受預防性治療。因此我們覺得我們能留住那些表現良好的病人。他們獲得具市場競爭力的療效。
Babar, you want to talk about the...
Babar,你要談一下那個……
Babar Ghias - Chief Financial Officer
Babar Ghias - Chief Financial Officer
Thanks, Stacy, for the question. Allow me to explain a little bit more perspective on the pharmacy. So look, at the end of the day, the progress of any product should be on patient demand and not inventory dynamics. And as Charlie mentioned in his remarks, the performance of a pharmacy can actually create a meaningful impact on the progress of the product. And when we made that switch, we were getting to a point of scaling the product that we needed to move with a larger partner who can support the vision for ORLADEYO and potentially navenibart when it gets approved.
謝謝你,Stacy,提出這個問題。讓我從藥局端再多補充一些觀點。所以你看,歸根結底,任何產品的進展應該取決於病人需求,而不是庫存動態。正如 Charlie 在他的發言中提到的,藥局的表現其實可能對產品的進展造成實質影響。而當我們做出那次切換時,我們的產品正走到需要擴大規模的階段,因此我們需要與一個更大型的合作夥伴合作,能支持 ORLADEYO 的願景,以及未來 navenibart 一旦獲批後的潛在需求。
So when we think about basically keeping the guidance, at the start of the year, we had a different pharmacy partner, we had a different operating model. It was not necessarily incorporating the dynamics of the inventory. As I said, what we do not want to do is artificially change the guidance because fundamentally, it should be about patient demand. So we are still in early days of that, so we did not feel the need that at this point in time we need to change the guidance for ORLADEYO just because we have a one-time inventory dynamic.
因此,當我們思考基本上維持指引時,在年初我們有不同的藥局合作夥伴,也有不同的營運模式。當時並不一定納入庫存動態的影響。如我所說,我們不希望因為本質上指引應該反映病人需求,而去人為地調整指引。所以我們仍處於非常早期的階段,因此我們不認為在此時此刻需要僅因一次性的庫存動態就調整 ORLADEYO 的指引。
And as I said, once we get past this quarter, as you can appreciate, it has only been six weeks that we have actually been fully with CareMed because the implementation started somewhere in the August timeframe, so call it six to eight weeks. We do not even have a full quarter under the belt. So as we get past through that, it should really reflect the patient demand. So that is why we were being a little bit careful and being conservative in terms of changing guidance at this point in time just because of an inventory dynamic.
而且如我所說,一旦我們度過本季,你也能理解,因為我們真正全面轉到 CareMed 才六週左右;導入大約是在 8 月那段時間開始,所以大概是六到八週。我們甚至還沒有完整跑完一個季度。因此,等我們走過這段期間後,數據應該會真正反映病人需求。這就是為什麼我們在此時此刻僅因庫存動態而調整指引時會比較謹慎、也比較保守。
Stacy Ku - Equity Analyst
Stacy Ku - Equity Analyst
Incredibly helpful. Thank you all.
非常有幫助。謝謝各位。
Operator
Operator
Tazeen Ahmad, Bank of America.
美國銀行(Bank of America)的 Tazeen Ahmad。
Unidentified Participant
Unidentified Participant
Great. Hi, this is [Jeremiah] on for Tazeen. Thanks for taking our question. I wanted to ask a question on the Netherton readout that's expected around year-end. I am just wondering what's the benchmark or what level of data you guys are looking for in order to move that program forward? I guess, depending on if the study hits, how quickly could you move to the pivotal stages? Thanks.
很好。大家好,我是 [Jeremiah],代替 Tazeen 發問。謝謝你們回答我們的問題。我想問一個關於預計在年底左右公布的 Netherton(奈瑟頓症候群)讀出結果的問題。我想了解,你們推進這個專案所期待的基準是什麼,或你們在尋找什麼程度的數據?我想,取決於研究是否達標,你們能多快進入關鍵性(pivotal)階段?謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Sandeep, you want to take that?
Sandeep,你要回答這題嗎?
Sandeep Menon - Chief Research and Development Officer
Sandeep Menon - Chief Research and Development Officer
Yeah, I will take that. No, thank you for the question. As you know, Netherton syndrome is a devastating skin disease, and that has got multiple other layers of disease manifestation, including immunity and inflammation.
好的,我來回答。不,謝謝你的提問。如你所知,奈瑟頓症候群是一種毀滅性的皮膚疾病,並且還有多層面的其他疾病表現,包括免疫與發炎。
We are getting ready for our data readout in December. What we will be presenting is the primary endpoint and the key secondary endpoints, along with obviously the safety and tolerability of that. And what good looks like at this point, these patients don't have any treatment options, and given the severity of the disease, any improvement, which is clinically meaningful, is still better than what patients don't have at this point. So we have talked to the patients and the relevant KOLs, and also in discussions very soon with the FDA to come up with a benchmark, basically
我們正在為 12 月的數據讀出做準備。我們將呈現主要終點與關鍵次要終點,當然也包括其安全性與耐受性。而就目前而言,什麼樣算是好的結果:這些病人沒有任何治療選項,且考量疾病的嚴重性,任何具有臨床意義的改善,都仍然優於病人目前所面臨的「沒有治療」狀態。因此我們已與病人及相關的關鍵意見領袖(KOL)交流,也將很快與 FDA 討論,以建立一個基準,基本上是這樣。
But from our perspective, as long as we are able to get 20% to 25% in the primary IASI score, I think it should be a pretty good clinically meaningful endpoint based on all the research that we have done internally, talking to the KOLs, and obviously the regulatory discussions are pending as well. So I think we will put it out there for now, and once the data reads out, we will share more.
但從我們的角度來看,只要我們能在主要的 IASI 分數上達到 20% 到 25% 的改善,我認為基於我們內部所做的所有研究、與 KOL 的討論,且當然也還有待監管機關的討論,我覺得這應該會是一個相當具有臨床意義的終點。所以我想我們先把這個標準提出來;等數據讀出後,我們會分享更多。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
And obviously within that, we will be looking for consistency in the fact as well. And so we will look at this a number of different ways. Do you want to just talk about what do we think next will be? Would we go straight to...
而且很明顯地,在此之中我們也會看一致性。因此我們會用多種不同方式來檢視這些結果。你要不要談一下我們認為接下來會怎麼走?我們會直接進入……
Sandeep Menon - Chief Research and Development Officer
Sandeep Menon - Chief Research and Development Officer
Yeah, the next basically, we will be reflecting on the totality of the data. And at this point, we want to do what is best for the program and for the patients. So we are not going to rush into anything that is a pivotal right away.
是的,接下來基本上我們會綜合評估整體數據。而在這個時間點,我們想做對這個專案與病人最好的事。所以我們不會立刻就匆忙進入任何關鍵性(pivotal)研究。
Depending on what the data is, we will talk to the regulators and digest the data. And because this is going to be the first in class, first therapy ever coming for Netherton, we want to be very clear in terms of where we want to take this. But we will be swift in decision-making, and we will move fast. At the same time, we will be very scientifically rigorous and thoughtful in how we take the clinical development forward.
取決於數據結果,我們會與監管機關溝通並消化這些數據。而且因為這將會是奈瑟頓症候群的同類首創(first-in-class)、也是史上第一個治療選項,我們希望非常清楚我們要把它推進到哪一步。但我們會迅速做出決策,並且快速推進。同時,我們也會以非常嚴謹的科學態度與周全的思考來推動臨床開發。
Unidentified Participant
Unidentified Participant
Very helpful. Thanks, guys.
非常有幫助。謝謝各位。
Operator
Operator
Maury Raycroft, Jefferies.
Jefferies 的 Maury Raycroft。
Maury Raycroft - Equity Analyst
Maury Raycroft - Equity Analyst
Good morning. Thanks for taking my questions. I will shift gears and maybe just ask one on BD. I guess with the new scientific advisory board, can you talk more about their mandate and what your latest thinking is related to BD and the type of assets you are looking to in-license?
早安。謝謝你們回答我的問題。我換個話題,想問一個關於 BD(商務拓展)的問題。我想,隨著新的科學顧問委員會成立,你們能否多談談他們的任務授權(mandate),以及你們目前對 BD 的最新想法,還有你們想引進授權(in-license)的資產類型?
Sandeep Menon - Chief Research and Development Officer
Sandeep Menon - Chief Research and Development Officer
So from our perspective -- thank you for the question, Maury. Our scientific advisory board, as you can see, it comes with a high pedigree and a very, very successful track record, including with Dr. Tony Manning, who is chairing the SAB. So it is a working scientific advisory board, like Charlie mentioned. It is not that people are coming in to get some luxurious seat on the board here. They are working with us, as we are, at least a few times a week.
從我們的角度來看——謝謝你的提問,Maury。我們的科學顧問委員會,如你所見,成員資歷非常優秀,且有非常、非常成功的紀錄,其中包括擔任 SAB 主席的 Tony Manning 醫師。因此這是一個如 Charlie 所提到的「運作型」科學顧問委員會。並不是有人來這裡只是為了在董事會上坐個豪華席位。他們與我們一起工作,就像我們一樣,至少每週會合作幾次。
We are rolling our sleeves, looking at multiple assets. As we have shared before, it is going to be early clinical assets, Phase I, Phase II. Mostly, we will go with very, very clear biology. We are not going to take chances on things that are far-fetched in terms of an inflection point. And we will ensure that this is sticking to our core strengths, because we have a commercial fabric that we are going to take advantage of. So that is what we are going to play, and you will see in the next few months, as we have more information, we will be ready to share.
我們正捲起袖子,評估多項資產。如同我們先前分享的,將會以早期臨床資產為主,包括第一期、第二期。大多數情況下,我們會選擇生物學機制非常、非常清楚的項目。對於在拐點上過於牽強的事情,我們不會去冒險。我們也會確保這些項目符合我們的核心優勢,因為我們有一個可加以運用的商業化基礎。
But the punchline here is the SAB is very, very seasoned. They have been there, done that, and we are working together as a team to get to a place where we have a pipeline that is going to be rich and valuable to our stakeholders
但這裡的重點是,SAB 非常、非常資深。他們經歷過、做過,我們正以團隊方式合作,目標是打造一條對我們利害關係人而言既豐富又有價值的研發管線。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
And Maury, just to add to that too, we have, of course, built a very strong internal team for both scientific evaluation and business development. So the internal team is generating the ideas, and then when we get excited about something, the SAB helps us really wrestle it to the ground.
另外,Maury,我也補充一下:我們當然也建立了一支非常強的內部團隊,涵蓋科學評估與商務開發兩方面。因此由內部團隊提出想法;當我們對某個方向感到興奮時,SAB 會協助我們把它真正落地、徹底釐清。
Is this something that we want to do? We think it is a great partnership. Early days, it is working very well, and we think that this is going to be very supportive to our strategy
這是不是我們想做的事?我們認為這是一個很棒的合作夥伴關係。目前仍在早期階段,但運作得非常好,我們也認為這將對我們的策略提供很大的支持。
Maury Raycroft - Equity Analyst
Maury Raycroft - Equity Analyst
Got it. That is helpful. And maybe just a quick follow-up on Netherton. As you guys are thinking about next steps with the program, in the press release, it mentions that expenses were lower related to the program in third quarter. I guess, any specific reasons there? Is it just because the study is enrolled and it is kind of at a status quo, or how should we think about that?
了解。這很有幫助。另外也想就 Netherton 再追問一下。當你們在思考該計畫的下一步時,新聞稿提到第三季與該計畫相關的費用較低。我想問,是否有任何具體原因?是因為研究已完成收案、目前大致維持現狀,還是我們應該如何理解?
Babar Ghias - Chief Financial Officer
Babar Ghias - Chief Financial Officer
Yeah, I think I will point it back to the financial discipline that we have been instituting across the organization, Maury, and basically taking an evidence-based approach. So I will give you an example.
是的,我想把這點回到我們在整個組織推行的財務紀律上,Maury,基本上是採取以證據為基礎的方法。我舉個例子。
Historically, we may have been a little bit aggressive in our sense that we need to do CMC campaign before we have actually seen results. I think what I was basically emphasizing earlier was we are taking a very evidence-based and rigorous scientific approach that, do we first have a product? Do we have the available data that allows us to unlock the next step of development?
過去我們可能稍微比較積極,覺得在真正看到結果之前就需要先做 CMC(化學、製造與管制)批次/活動。我先前強調的是:我們正在採取非常以證據為基礎、且嚴謹的科學方法——首先,我們是否真的有一個產品?我們是否擁有足夠的可用數據,讓我們能解鎖下一步的開發?
So I think across the organization, we have been instituting that discipline. Netherton, like I said, that was a perfect example where we did not feel that we need to spend dollars at risk on things before we actually can unlock the data. So that was basically the primary reason why you see a declining expense. So I think that is going to be a theme, right? That is how we are going to go about and develop on this innovation aspect that we are talking about BD, but also being very committed to delivering strong profitability going forward.
因此我認為,我們在整個組織都在建立這樣的紀律。以 Netherton 為例,如我所說,這是個完美案例:在我們尚未能解鎖數據之前,我們不認為需要在高風險事項上先行投入資金。所以這基本上就是你看到費用下降的主要原因。我認為這會成為一個主題,對吧?這就是我們推動我們所談的 BD 創新面向的方式,同時也非常致力於在未來交付強勁的獲利能力。
Sandeep Menon - Chief Research and Development Officer
Sandeep Menon - Chief Research and Development Officer
And Maury, just to add what Babar nicely summarized, we will ensure that we are still very swift. It is not that we are going to just make it so sequential that we will delay the program, and that is not what it is. Basically, we will get some early data and we will take the right bets that is going to give us scientific and development success.
另外,Maury,補充 Babar 很好地總結的內容:我們也會確保行動仍然非常迅速。並不是說我們會把流程做得完全線性、以致於延誤計畫,並非如此。基本上,我們會先取得一些早期數據,然後做出正確的押注,以帶來科學與開發上的成功。
Maury Raycroft - Equity Analyst
Maury Raycroft - Equity Analyst
Got it. Okay. Thanks for taking my questions.
了解。好的,謝謝回答我的問題。
Operator
Operator
Jessica Fye, JPMorgan.
Jessica Fye,摩根大通(JPMorgan)。
Unidentified Participant
Unidentified Participant
This is [Silvia] on for Jess Fye. Thanks for taking our question. To confirm, with the prior model pre-CareMed, was there any inventory sitting elsewhere that needs to be worked down that maybe leads to the hesitation to update the ORLADEYO guide?
我是 [Silvia],代 Jess Fye 提問。謝謝接受我們的問題。想確認一下,在 CareMed 之前的舊模式下,是否有任何庫存放在其他地方需要去化,因而導致你們對更新 ORLADEYO 指引有所保留?
And as a follow-up, and appreciate the conservatism so soon after the specialty pharmacy shift, but if the high teens inventory benefit was not contemplated in the fundamental ORLADEYO guidance you laid out and are maintaining, would it be wrong for investors to expect full-year ORLADEYO revenue landing in the $650 million to $655 million range, which is just the midpoint of the fundamental guidance plus $15 million to $20 million? Thanks.
另外追問一下,也理解在專科藥局轉換後不久採取保守作法;但如果「十幾個百分點」的庫存效益並未納入你們所提出且仍維持的 ORLADEYO 基本指引之中,那投資人預期全年 ORLADEYO 營收落在 6.50 億至 6.55 億美元區間(也就是基本指引中點再加上 1,500 萬至 2,000 萬美元)是否不合理?謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, [Silvia]. First of all, from inventory from the prior pharmacy, the billing model was different there. There, it was a flash sale for every pack that went out, so there basically was no inventory. And with CareMed, it's a little bit more traditional pharmacy model where they buy some inventory, as Babar described. It's at a relatively low level, about a week's worth of inventory.
謝謝,[Silvia]。首先,關於先前藥局的庫存,當時的計費模式不同。那邊是每一盒出貨就立即認列銷售(flash sale),所以基本上沒有庫存。而在 CareMed 這邊,則是較傳統的藥局模式,他們會購買一些庫存,如同 Babar 所描述。庫存水位相對低,大約是一週的庫存量。
And no, from the guidance perspective, with everything we see at this point and with the changes that, as we're saying, we still haven't worked through completely, we see the range of $625 million to $645 million is still the right guidance for the year.
至於指引方面,不會。就我們目前所見,以及如我們所說仍未完全消化完的變動而言,我們認為全年 6.25 億至 6.45 億美元的區間仍是今年正確的指引。
Operator
Operator
Serge Belanger,
Serge Belanger,
Unidentified Participant
Unidentified Participant
Good morning, everyone. This is [John] on for Serge today. Thanks for taking our questions. Just a couple on ORLADEYO. First, curious if you could provide an update on the paid Rx rate exiting the third quarter, and if your outlook has changed on where this could reach considering the efficiencies yielded from the CareMed partnership.
各位早安。今天我是 [John],代 Serge 提問。謝謝接受我們的問題。我有幾個關於 ORLADEYO 的問題。首先,想請你們更新一下第三季結束時的付費處方(paid Rx)比率;以及考量 CareMed 合作帶來的效率,你們對該比率可達到的水準之展望是否有所改變?
And then second, on the pediatric side of things, you highlighted the launch is progressing ahead of expectations. Just curious how you view the overall opportunity now versus the original 500-patient pool. Thanks.
第二,關於兒科方面,你們提到上市推進超出預期。想請教你們現在如何看待整體機會,相較於原先估計的 500 名病患池。謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, John. As far as the paid rate, just recall what typically happens in the second half of the year is our paid rate typically peaks in the second quarter after going through all the reauthorizations in the first part of the year. And then in the second half of the year, it starts to gradually tick down, mainly because the rate is driven more by new patients coming on, and new patients don't get to the 80%-plus paid rate that we had in the overall population as quickly. So we're seeing that same dynamic right in line with our expectations. I think we ended the quarter somewhere around 82%, 83% paid.
謝謝,John。關於付費比率,請回想一下通常在下半年會發生的情況:我們的付費比率通常在第二季達到高峰,因為上半年已完成所有重新授權(reauthorizations)。而在下半年,它會開始逐步下滑,主要是因為該比率更多是由新進病患所驅動;新病患不會像整體族群那樣,能那麼快達到我們所看到的 80% 以上付費比率。因此我們看到的動態與我們的預期一致。我想我們在季末大約是 82%、83% 的付費。
To your question around CareMed, we do think with their capabilities working with our team, it gives us the opportunity to meet and potentially exceed our long-term goal of getting to 85% paid rate as kind of a steady state. So we think we're on track for that.
至於你問到 CareMed,我們確實認為,憑藉他們的能力並與我們團隊合作,讓我們有機會達成、甚至可能超越我們的長期目標——也就是在穩態下達到 85% 的付費比率。因此我們認為進度符合預期。
I'll note that with pediatrics too, we're seeing excellent early paid rates. Pediatrics, as you would expect, is basically a commercial plus Medicaid business, so a little bit different dynamic than our overall population. But the early signs are we're getting these kids at a high rate to pay, and I expect that to continue.
我也想補充一下,在兒科方面,我們也看到非常優異的早期已付費率。如你所預期,兒科基本上是以商業保險加上 Medicaid(醫療補助)為主的業務,因此相較於我們整體族群,動態略有不同。但早期跡象顯示,這些孩子的付費比例很高,我預期這種情況會持續。
And then as far as the overall opportunity for peds, yeah, we're cautiously optimistic that it could end up being bigger than we originally expected. It certainly is turning out to be that this year. I think we need a couple quarters in addition, at least, to see what the steady state in terms of demand. There are still physicians out there who are still learning about this indication and have not acted yet. So I think there is likely a lot more opportunity than the 500 diagnosed and treated patients that we have previously prescribed.
至於兒科整體的機會,是的,我們審慎樂觀,最終可能會比我們原先預期的更大。今年的確呈現出這樣的趨勢。我認為我們至少還需要再觀察幾個季度,才能看清需求的穩態會是什麼樣子。目前仍有一些醫師正在了解這個適應症,尚未採取行動。因此,我認為機會很可能遠不止我們先前所提到的 500 名已診斷並接受治療的患者。
Operator
Operator
John Wolleben, Citizens.
John Wolleben,Citizens。
Unidentified Participant
Unidentified Participant
This is [Catherine] on for John. I just have a quick clarification question about the number of patient adds. I know you said that the patient adds have been kind of tracking along the average from quarter by quarter. I just want to provide a little bit more color on how that is tracking and what your expectations are for the fourth quarter based on your revenue guidance. Thank you.
我是代替 John 的 [Catherine]。我想就新增患者數量做一個簡短的釐清提問。我知道你提到新增患者數一直大致沿著季度平均水準在走。我想請你再多提供一些細節,說明目前的追蹤情況,以及基於你們的營收指引,對第四季的預期為何。謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, [Catherine]. What we described is that new patient prescriptions coming in has been very much in line, and the net patient adds in the third quarter were quite healthy. So we expect, particularly with our transition to CareMed, with the continued demand, with the strong demand in peds, that we would expect another good quarter in the fourth quarter, and that this trend will largely continue into 2027.
謝謝你,[Catherine]。我們的描述是,新患者處方的進入量一直非常符合趨勢,而第三季的淨新增患者數相當健康。因此我們預期,特別是在我們轉換至 CareMed 之後,隨著需求持續、以及兒科需求強勁,我們預期第四季也會是另一個不錯的季度,而且這個趨勢大致會延續到 2027 年。
Unidentified Participant
Unidentified Participant
Perfect. Thank you.
很好。謝謝。
Operator
Operator
Brian Abrahams, RBC Capital Markets.
Brian Abrahams,RBC Capital Markets。
Brian Abrahams - Analyst
Brian Abrahams - Analyst
Hi there. Good morning. Thanks for taking our question. I am curious, are you seeing any effects on ORLADEYO use patterns from the recent launch of oral on-demand or other long-acting injectable therapies for prophylaxis? And then, I guess, secondarily, curious what your market research tells you about the potential opportunity differences if navenibart can demonstrate every six-month dosing versus every three months. Thanks.
你好。早安。謝謝讓我們提問。我想了解的是,近期口服按需用藥(on-demand)或其他用於預防的長效注射療法上市後,你們是否看到對 ORLADEYO 使用模式有任何影響?另外,我也想請教,你們的市場研究是否顯示:若 navenibart 能證明可每六個月給藥一次,相較於每三個月一次,在潛在機會上會有哪些差異?謝謝。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thanks, Brian. We have said before, and at this point, it has been over a year since the oral acute came onto the market, and then also the two new prophies that came on last summer. We are really not seeing any impact from the oral acute patients.
謝謝你,Brian。我們之前就說過,到目前為止,口服急性用藥上市已經超過一年,另外兩個新的預防用藥也在去年夏天上市。我們確實沒有看到口服急性用藥患者對我們造成任何影響。
Some ORLADEYO patients are using it. We are certainly not seeing any negative trends, nor would I say it is anything particularly positive. It just has not had that much of an impact on our business. The oral, or sorry, the other longer-acting injectables, what we are really seeing there is that when a patient ORLADEYO does not work out for them, instead of moving preferentially to TAKHZYRO, more of those patients are going either to ANDEMBRY or DAWNZERA, and that is what you would expect.
有些 ORLADEYO 患者會使用它。我們當然沒有看到任何負面趨勢,但我也不會說有什麼特別正面的影響。它對我們的業務影響並不大。至於其他長效注射劑,我們真正看到的是:當某位患者使用 ORLADEYO 的效果不如預期時,這些患者不再優先轉用 TAKHZYRO,而是有更多人改用 ANDEMBRY 或 DAWNZERA,這也符合預期。
And then with navenibart, what we're seeing, again, in all the research that we've done, three months is really a transformative. Every three months dosing is really transformative. And then having the ability to have three months and six months as an option makes the whole package even better. And so we expect to get both doses in our label, certainly based on the Phase II data that we've seen with both doses having very durable reduction in attacks.
至於 navenibart,我們在所有已完成的研究中看到的是:每三個月一次確實具有顛覆性。每三個月給藥一次確實是顛覆性的。而若能同時提供每三個月與每六個月作為選項,整體方案就更具吸引力。因此我們預期標籤上能同時納入兩種劑量,當然這是基於我們在第二期試驗中看到兩種劑量都能非常持久地降低發作次數。
And to have that option, and we don't know yet which dosage form would be which frequency would be most used. I think that's something we'll learn more about. But to have both really makes navenibart a very strong option for patients and physicians. Very, really, really intriguing to them.
能有這樣的選項,而且我們目前還不知道哪一種劑型、哪一種給藥頻率會被使用得最多。我想這是我們之後會更清楚的事情。但同時具備兩者,確實讓 navenibart 成為患者與醫師非常強而有力的選擇。對他們而言非常、非常、非常有吸引力。
Brian Abrahams - Analyst
Brian Abrahams - Analyst
Thank you.
謝謝。
Operator
Operator
This concludes the question-and-answer session. I would now like to turn it back to Charlie Gayer for closing remarks.
問答環節到此結束。接下來我想把時間交回給 Charlie Gayer 作結語。
Charles Gayer - President, Chief Executive Officer, Director
Charles Gayer - President, Chief Executive Officer, Director
Thank you. So as we've described here, another really strong quarter from BioCryst as we've gone through a year of transformation, both in leadership, in strategy, in how we run the business. And I'd also like to thank everybody, all our colleagues at BioCryst who've worked so hard during this year of transition. And I think we've set ourselves up for a really great 2027 and beyond. So thank you, everyone.
謝謝。如同我們在此所說,BioCryst 又交出一個非常強勁的季度表現,因為我們走過了一整年的轉型期,無論是在領導層、策略,或是我們經營業務的方式上。我也想感謝所有人,感謝 BioCryst 的所有同仁在這一年轉型期間的辛勤付出。我認為我們已為 2027 年及其後的發展奠定了非常好的基礎。所以謝謝大家。
Operator
Operator
Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.
感謝各位參與今天的電話會議。本次會議到此結束。各位現在可以掛線。